Details for Patent: 8,999,932
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which drugs does patent 8,999,932 protect, and when does it expire?
Patent 8,999,932 protects PARSABIV and is included in one NDA.
This patent has fifty-two patent family members in twenty-nine countries.
Summary for Patent: 8,999,932
| Title: | Therapeutic agents for reducing parathyroid hormone levels |
| Abstract: | Compounds having activity for lowering parathyroid hormone levels are described. In one embodiment, the compounds are comprised of a contiguous sequence of subunits, X.sub.1-X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.sub.6-X.sub.7, wherein the X.sub.1 subunit comprises a thiol-containing moiety and the distribution of charge on the X.sub.2-X.sub.7 subunits provides the desired activity. Methods of using the compounds for treating hyperparathyroidism, bone disease and/or hypercalcemic disorders are also described, and in particular, methods for lowering plasma PTH and serum calcium are provided. The compounds can be used to treat subjects having, for example: primary, secondary or tertiary hyperparathyroidism; hypercalcemia of malignancy; metastatic bone disease; or osteoporosis. |
| Inventor(s): | Karim; Felix (Walnut Creek, CA), Baruch; Amos (San Francisco, CA), Maclean; Derek (Los Altos, CA), Das; Kanad (San Francisco, CA), Yin; Qun (Palo Alto, CA) |
| Assignee: | KAI Pharmaceuticals, Inc. (South San Francisco, CA) |
| Application Number: | 12/846,724 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,999,932 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Compound; |
Drugs Protected by US Patent 8,999,932
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kai Pharms Inc | PARSABIV | etelcalcetide | SOLUTION;INTRAVENOUS | 208325-001 | Feb 7, 2017 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | Y | A METHOD OF TREATING SECONDARY HYPERPARATHYROIDISM (SHPT) | See Plans and Pricing | ||
| Kai Pharms Inc | PARSABIV | etelcalcetide | SOLUTION;INTRAVENOUS | 208325-002 | Feb 7, 2017 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | Y | A METHOD OF TREATING SECONDARY HYPERPARATHYROIDISM (SHPT) | See Plans and Pricing | ||
| Kai Pharms Inc | PARSABIV | etelcalcetide | SOLUTION;INTRAVENOUS | 208325-003 | Feb 7, 2017 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | Y | A METHOD OF TREATING SECONDARY HYPERPARATHYROIDISM (SHPT) | See Plans and Pricing | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,999,932
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2010278897 | See Plans and Pricing | |||
| Brazil | 112012002143 | See Plans and Pricing | |||
| Canada | 2769525 | See Plans and Pricing | |||
| China | 102711789 | See Plans and Pricing | |||
| China | 107674114 | See Plans and Pricing | |||
| Cyprus | 1118388 | See Plans and Pricing | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
